• Text Resize A A A
  • Print Print
  • Share Share on facebook Share on twitter Share
FOR IMMEDIATE RELEASE
August 17, 2017
Contact: HHS Press Office
202-690-6343
media@hhs.gov

HHS Secretary Price: Agreement with Mylan a Victory for Americans Who Rely on Lifesaving EpiPen

Agreement supports President Trump’s goal of lowering drug costs by saving taxpayers hundreds of millions of dollars

Health and Human Services Secretary Tom Price, M.D. released the following statement today after the announcement of an agreement with Mylan, the manufacturer of EpiPen to reclassify the auto injection medical device, a move that will save taxpayers hundreds of millions of dollars. The agreement will reclassify EpiPen as a brand name drug consistent with the Medicaid statute and regulations. Mylan has agreed to use the correct reference price of the 3rd quarter of 1990 for the purpose of calculating inflationary payment rebates under the Medicaid Drug Rebate (MDR) program. These changes will be effective retroactive to April 1, 2017.

“Mylan’s agreement to reclassify EpiPen is a tremendous victory for Americans who rely on this important lifesaving device and especially for Medicaid beneficiaries across the country,” said Price. “CMS Administrator Seema Verma and the team at HHS are working every day in support of President Trump’s goal of lowering the costs of drugs and medical devices in our country and making healthcare more affordable.”

###
Note: All HHS press releases, fact sheets and other news materials are available at https://www.hhs.gov/news.
Like HHS on Facebook Exit disclaimer icon, follow HHS on Twitter @HHSgov Exit disclaimer icon, and sign up for HHS Email Updates.
Last revised: August 17, 2017

Subscribe to RSS

Receive latest updates

Subscribe to our RSS